EUVIMEDEUVIMED entdecken
Crossref

Mucosal SARS-CoV-2 Nanoparticle Vaccine Based on Mucosal Adjuvants and Its Immune Effectiveness by Intranasal Administration

Lucheng Xiao, Weili Yu, Lijuan Shen, Wenying Yan, Jinming Qi, Tao Hu iD

ACS Applied Materials & Interfaces · 2023

DOI: 10.1021/acsami.3c05456 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2023. Verfasst von Lucheng Xiao und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, 1 Bei-Er-Jie Street, Haidian District…. Hauptthemen laut MEDLINE: COVID-19, Nanoparticles. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Beijing Municipal Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19NanoparticlesHumansAnimalsMiceCOVID-19 VaccinesSARS-CoV-2Antibodies, ViralAdministration, IntranasalAdjuvants, ImmunologicAdjuvants, Pharmaceutic

Stichwörter der Autor:innen

SARS-CoV-2intranasal administrationmucosal adjuvantnanoparticle vaccinereceptor-binding domain

Substanzen

COVID-19 VaccinesAntibodies, ViralAdjuvants, ImmunologicAdjuvants, Pharmaceutic

Autor:innen und Institutionen

  • State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, 1 Bei-Er-Jie Street, Haidian District, Beijing 100190, China.
  • University of Chinese Academy of Sciences, 19 Yuquan Road, Shijingshan District, Beijing 100049, China.

ORCID-Profile: Tao Hu

Förderung

  • National Key Research and Development Program of China
  • Beijing Municipal Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Xiao, L., Yu, W., Shen, L., Yan, W., Qi, J., & Hu, T. (2023). Mucosal SARS-CoV-2 Nanoparticle Vaccine Based on Mucosal Adjuvants and Its Immune Effectiveness by Intranasal Administration. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.3c05456

Vancouver

Xiao L, Yu W, Shen L, Yan W, Qi J, Hu T. Mucosal SARS-CoV-2 Nanoparticle Vaccine Based on Mucosal Adjuvants and Its Immune Effectiveness by Intranasal Administration. ACS Applied Materials & Interfaces. 2023. doi:10.1021/acsami.3c05456

BibTeX
@article{Xiao2023,
  author = {Xiao, Lucheng and Yu, Weili and Shen, Lijuan and Yan, Wenying and Qi, Jinming and Hu, Tao},
  title = {Mucosal SARS-CoV-2 Nanoparticle Vaccine Based on Mucosal Adjuvants and Its Immune Effectiveness by Intranasal Administration},
  journal = {ACS Applied Materials & Interfaces},
  year = {2023},
  doi = {10.1021/acsami.3c05456}
}
Kostenlos starten →